PMC:7324763 / 43411-47828 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T777","span":{"begin":17,"end":25},"obj":"SP_7"},{"id":"T96710","span":{"begin":17,"end":25},"obj":"SP_7"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T563","span":{"begin":243,"end":251},"obj":"Body_part"},{"id":"T564","span":{"begin":271,"end":273},"obj":"Body_part"},{"id":"T565","span":{"begin":377,"end":385},"obj":"Body_part"},{"id":"T566","span":{"begin":2193,"end":2195},"obj":"Body_part"},{"id":"T567","span":{"begin":2204,"end":2206},"obj":"Body_part"},{"id":"T568","span":{"begin":2316,"end":2321},"obj":"Body_part"},{"id":"T569","span":{"begin":2333,"end":2335},"obj":"Body_part"},{"id":"T570","span":{"begin":2569,"end":2572},"obj":"Body_part"},{"id":"T571","span":{"begin":2647,"end":2650},"obj":"Body_part"},{"id":"T572","span":{"begin":2832,"end":2840},"obj":"Body_part"},{"id":"T573","span":{"begin":3077,"end":3079},"obj":"Body_part"}],"attributes":[{"id":"A563","pred":"fma_id","subj":"T563","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A564","pred":"fma_id","subj":"T564","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A565","pred":"fma_id","subj":"T565","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A566","pred":"fma_id","subj":"T566","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A567","pred":"fma_id","subj":"T567","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A568","pred":"fma_id","subj":"T568","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A569","pred":"fma_id","subj":"T569","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A570","pred":"fma_id","subj":"T570","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A571","pred":"fma_id","subj":"T571","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A572","pred":"fma_id","subj":"T572","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A573","pred":"fma_id","subj":"T573","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T322","span":{"begin":17,"end":25},"obj":"Disease"},{"id":"T323","span":{"begin":328,"end":335},"obj":"Disease"},{"id":"T324","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"T325","span":{"begin":488,"end":495},"obj":"Disease"},{"id":"T326","span":{"begin":555,"end":562},"obj":"Disease"},{"id":"T327","span":{"begin":616,"end":623},"obj":"Disease"},{"id":"T328","span":{"begin":687,"end":694},"obj":"Disease"},{"id":"T329","span":{"begin":754,"end":761},"obj":"Disease"},{"id":"T330","span":{"begin":852,"end":859},"obj":"Disease"},{"id":"T331","span":{"begin":1006,"end":1013},"obj":"Disease"},{"id":"T332","span":{"begin":1241,"end":1248},"obj":"Disease"},{"id":"T333","span":{"begin":1367,"end":1374},"obj":"Disease"},{"id":"T334","span":{"begin":1483,"end":1490},"obj":"Disease"},{"id":"T335","span":{"begin":1505,"end":1512},"obj":"Disease"},{"id":"T336","span":{"begin":1526,"end":1543},"obj":"Disease"},{"id":"T337","span":{"begin":1537,"end":1543},"obj":"Disease"},{"id":"T338","span":{"begin":1639,"end":1646},"obj":"Disease"},{"id":"T339","span":{"begin":1826,"end":1833},"obj":"Disease"},{"id":"T340","span":{"begin":1930,"end":1937},"obj":"Disease"},{"id":"T341","span":{"begin":2020,"end":2027},"obj":"Disease"},{"id":"T342","span":{"begin":2112,"end":2119},"obj":"Disease"},{"id":"T343","span":{"begin":2210,"end":2213},"obj":"Disease"},{"id":"T344","span":{"begin":2270,"end":2277},"obj":"Disease"},{"id":"T345","span":{"begin":2421,"end":2428},"obj":"Disease"},{"id":"T346","span":{"begin":2546,"end":2553},"obj":"Disease"},{"id":"T347","span":{"begin":2634,"end":2641},"obj":"Disease"},{"id":"T348","span":{"begin":2683,"end":2686},"obj":"Disease"},{"id":"T350","span":{"begin":2697,"end":2704},"obj":"Disease"},{"id":"T351","span":{"begin":2793,"end":2800},"obj":"Disease"},{"id":"T352","span":{"begin":2935,"end":2944},"obj":"Disease"},{"id":"T353","span":{"begin":2945,"end":2952},"obj":"Disease"},{"id":"T354","span":{"begin":3057,"end":3064},"obj":"Disease"},{"id":"T355","span":{"begin":3102,"end":3114},"obj":"Disease"},{"id":"T356","span":{"begin":3118,"end":3122},"obj":"Disease"},{"id":"T357","span":{"begin":3250,"end":3257},"obj":"Disease"},{"id":"T358","span":{"begin":3385,"end":3392},"obj":"Disease"},{"id":"T359","span":{"begin":3504,"end":3511},"obj":"Disease"},{"id":"T360","span":{"begin":3602,"end":3609},"obj":"Disease"},{"id":"T361","span":{"begin":3738,"end":3745},"obj":"Disease"},{"id":"T362","span":{"begin":3812,"end":3816},"obj":"Disease"},{"id":"T363","span":{"begin":3886,"end":3893},"obj":"Disease"},{"id":"T364","span":{"begin":4039,"end":4046},"obj":"Disease"},{"id":"T365","span":{"begin":4066,"end":4069},"obj":"Disease"},{"id":"T367","span":{"begin":4157,"end":4164},"obj":"Disease"},{"id":"T368","span":{"begin":4237,"end":4244},"obj":"Disease"}],"attributes":[{"id":"A322","pred":"mondo_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A323","pred":"mondo_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A324","pred":"mondo_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A325","pred":"mondo_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A326","pred":"mondo_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A327","pred":"mondo_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A328","pred":"mondo_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A329","pred":"mondo_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A330","pred":"mondo_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A331","pred":"mondo_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A332","pred":"mondo_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A333","pred":"mondo_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A334","pred":"mondo_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A335","pred":"mondo_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A336","pred":"mondo_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/MONDO_0024880"},{"id":"A337","pred":"mondo_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A338","pred":"mondo_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A339","pred":"mondo_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A340","pred":"mondo_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A341","pred":"mondo_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A342","pred":"mondo_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A343","pred":"mondo_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/MONDO_0006687"},{"id":"A344","pred":"mondo_id","subj":"T344","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A345","pred":"mondo_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A346","pred":"mondo_id","subj":"T346","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A347","pred":"mondo_id","subj":"T347","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A348","pred":"mondo_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A349","pred":"mondo_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A350","pred":"mondo_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A351","pred":"mondo_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A352","pred":"mondo_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A353","pred":"mondo_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A354","pred":"mondo_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A355","pred":"mondo_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A356","pred":"mondo_id","subj":"T356","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A357","pred":"mondo_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A358","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A359","pred":"mondo_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A360","pred":"mondo_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A361","pred":"mondo_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A362","pred":"mondo_id","subj":"T362","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A363","pred":"mondo_id","subj":"T363","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A364","pred":"mondo_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A365","pred":"mondo_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A366","pred":"mondo_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A367","pred":"mondo_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A368","pred":"mondo_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T565","span":{"begin":363,"end":368},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T566","span":{"begin":468,"end":470},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T567","span":{"begin":592,"end":593},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T568","span":{"begin":1209,"end":1210},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T569","span":{"begin":2000,"end":2001},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T570","span":{"begin":2010,"end":2012},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T571","span":{"begin":2193,"end":2197},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T572","span":{"begin":2204,"end":2208},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T573","span":{"begin":2316,"end":2321},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T574","span":{"begin":3021,"end":3022},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T575","span":{"begin":3579,"end":3580},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T231","span":{"begin":271,"end":273},"obj":"Chemical"},{"id":"T233","span":{"begin":303,"end":305},"obj":"Chemical"},{"id":"T234","span":{"begin":457,"end":459},"obj":"Chemical"},{"id":"T235","span":{"begin":651,"end":653},"obj":"Chemical"},{"id":"T236","span":{"begin":722,"end":724},"obj":"Chemical"},{"id":"T237","span":{"begin":829,"end":831},"obj":"Chemical"},{"id":"T238","span":{"begin":975,"end":977},"obj":"Chemical"},{"id":"T239","span":{"begin":1049,"end":1060},"obj":"Chemical"},{"id":"T240","span":{"begin":1115,"end":1117},"obj":"Chemical"},{"id":"T241","span":{"begin":1336,"end":1338},"obj":"Chemical"},{"id":"T242","span":{"begin":1402,"end":1412},"obj":"Chemical"},{"id":"T243","span":{"begin":1452,"end":1454},"obj":"Chemical"},{"id":"T244","span":{"begin":1563,"end":1574},"obj":"Chemical"},{"id":"T245","span":{"begin":1606,"end":1608},"obj":"Chemical"},{"id":"T246","span":{"begin":1704,"end":1706},"obj":"Chemical"},{"id":"T247","span":{"begin":1784,"end":1786},"obj":"Chemical"},{"id":"T248","span":{"begin":1897,"end":1899},"obj":"Chemical"},{"id":"T249","span":{"begin":2138,"end":2148},"obj":"Chemical"},{"id":"T250","span":{"begin":2171,"end":2181},"obj":"Chemical"},{"id":"T251","span":{"begin":2193,"end":2195},"obj":"Chemical"},{"id":"T253","span":{"begin":2204,"end":2206},"obj":"Chemical"},{"id":"T255","span":{"begin":2236,"end":2238},"obj":"Chemical"},{"id":"T256","span":{"begin":2333,"end":2335},"obj":"Chemical"},{"id":"T258","span":{"begin":2388,"end":2390},"obj":"Chemical"},{"id":"T259","span":{"begin":2446,"end":2456},"obj":"Chemical"},{"id":"T260","span":{"begin":2519,"end":2521},"obj":"Chemical"},{"id":"T261","span":{"begin":2566,"end":2568},"obj":"Chemical"},{"id":"T262","span":{"begin":2601,"end":2603},"obj":"Chemical"},{"id":"T263","span":{"begin":2644,"end":2646},"obj":"Chemical"},{"id":"T264","span":{"begin":2761,"end":2763},"obj":"Chemical"},{"id":"T265","span":{"begin":2857,"end":2862},"obj":"Chemical"},{"id":"T266","span":{"begin":3077,"end":3079},"obj":"Chemical"},{"id":"T268","span":{"begin":3174,"end":3185},"obj":"Chemical"},{"id":"T269","span":{"begin":3221,"end":3223},"obj":"Chemical"},{"id":"T270","span":{"begin":3276,"end":3287},"obj":"Chemical"},{"id":"T271","span":{"begin":3312,"end":3326},"obj":"Chemical"},{"id":"T272","span":{"begin":3352,"end":3354},"obj":"Chemical"},{"id":"T273","span":{"begin":3430,"end":3444},"obj":"Chemical"},{"id":"T274","span":{"begin":3445,"end":3459},"obj":"Chemical"},{"id":"T275","span":{"begin":3523,"end":3537},"obj":"Chemical"},{"id":"T276","span":{"begin":3549,"end":3562},"obj":"Chemical"},{"id":"T277","span":{"begin":3629,"end":3642},"obj":"Chemical"},{"id":"T278","span":{"begin":3667,"end":3681},"obj":"Chemical"},{"id":"T279","span":{"begin":3682,"end":3695},"obj":"Chemical"},{"id":"T280","span":{"begin":3710,"end":3712},"obj":"Chemical"},{"id":"T281","span":{"begin":3761,"end":3774},"obj":"Chemical"},{"id":"T282","span":{"begin":3859,"end":3861},"obj":"Chemical"},{"id":"T283","span":{"begin":3939,"end":3953},"obj":"Chemical"},{"id":"T284","span":{"begin":4120,"end":4122},"obj":"Chemical"},{"id":"T285","span":{"begin":4172,"end":4177},"obj":"Chemical"},{"id":"T286","span":{"begin":4179,"end":4187},"obj":"Chemical"},{"id":"T287","span":{"begin":4247,"end":4262},"obj":"Chemical"},{"id":"T288","span":{"begin":4253,"end":4262},"obj":"Chemical"},{"id":"T289","span":{"begin":4263,"end":4272},"obj":"Chemical"},{"id":"T290","span":{"begin":4287,"end":4289},"obj":"Chemical"}],"attributes":[{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A232","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A235","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A236","pred":"chebi_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A237","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A238","pred":"chebi_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A240","pred":"chebi_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A241","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A246","pred":"chebi_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A247","pred":"chebi_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A248","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A249","pred":"chebi_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A251","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A252","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A254","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A257","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A258","pred":"chebi_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A259","pred":"chebi_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A260","pred":"chebi_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A261","pred":"chebi_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A262","pred":"chebi_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A263","pred":"chebi_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A264","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A265","pred":"chebi_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A266","pred":"chebi_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A267","pred":"chebi_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A268","pred":"chebi_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/CHEBI_31397"},{"id":"A269","pred":"chebi_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A270","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_31397"},{"id":"A271","pred":"chebi_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A272","pred":"chebi_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A273","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A274","pred":"chebi_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/CHEBI_17650"},{"id":"A275","pred":"chebi_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/CHEBI_17650"},{"id":"A276","pred":"chebi_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A277","pred":"chebi_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A278","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A279","pred":"chebi_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A280","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A281","pred":"chebi_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A283","pred":"chebi_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A284","pred":"chebi_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A285","pred":"chebi_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/CHEBI_35475"},{"id":"A286","pred":"chebi_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A287","pred":"chebi_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/CHEBI_50629"},{"id":"A288","pred":"chebi_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A289","pred":"chebi_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1326","span":{"begin":271,"end":275},"obj":"Gene"},{"id":"1327","span":{"begin":343,"end":347},"obj":"Gene"},{"id":"1328","span":{"begin":1397,"end":1401},"obj":"Gene"},{"id":"1329","span":{"begin":2133,"end":2137},"obj":"Gene"},{"id":"1330","span":{"begin":2166,"end":2170},"obj":"Gene"},{"id":"1331","span":{"begin":2193,"end":2197},"obj":"Gene"},{"id":"1332","span":{"begin":2204,"end":2208},"obj":"Gene"},{"id":"1333","span":{"begin":2333,"end":2338},"obj":"Gene"},{"id":"1334","span":{"begin":2344,"end":2348},"obj":"Gene"},{"id":"1335","span":{"begin":2441,"end":2445},"obj":"Gene"},{"id":"1336","span":{"begin":2476,"end":2480},"obj":"Gene"},{"id":"1337","span":{"begin":2644,"end":2650},"obj":"Gene"},{"id":"1338","span":{"begin":2812,"end":2816},"obj":"Gene"},{"id":"1339","span":{"begin":2818,"end":2822},"obj":"Gene"},{"id":"1340","span":{"begin":2853,"end":2862},"obj":"Gene"},{"id":"1341","span":{"begin":3077,"end":3081},"obj":"Gene"},{"id":"1342","span":{"begin":4247,"end":4252},"obj":"Gene"},{"id":"1343","span":{"begin":2566,"end":2572},"obj":"Gene"},{"id":"1344","span":{"begin":180,"end":188},"obj":"Species"},{"id":"1345","span":{"begin":940,"end":948},"obj":"Species"},{"id":"1346","span":{"begin":1544,"end":1552},"obj":"Species"},{"id":"1347","span":{"begin":2705,"end":2713},"obj":"Species"},{"id":"1348","span":{"begin":3817,"end":3825},"obj":"Species"},{"id":"1349","span":{"begin":3123,"end":3131},"obj":"Species"},{"id":"1350","span":{"begin":318,"end":335},"obj":"Disease"},{"id":"1351","span":{"begin":422,"end":430},"obj":"Disease"},{"id":"1352","span":{"begin":488,"end":508},"obj":"Disease"},{"id":"1353","span":{"begin":545,"end":562},"obj":"Disease"},{"id":"1354","span":{"begin":606,"end":636},"obj":"Disease"},{"id":"1355","span":{"begin":687,"end":707},"obj":"Disease"},{"id":"1356","span":{"begin":744,"end":761},"obj":"Disease"},{"id":"1357","span":{"begin":852,"end":860},"obj":"Disease"},{"id":"1358","span":{"begin":925,"end":939},"obj":"Disease"},{"id":"1359","span":{"begin":1006,"end":1014},"obj":"Disease"},{"id":"1360","span":{"begin":1231,"end":1248},"obj":"Disease"},{"id":"1361","span":{"begin":1367,"end":1375},"obj":"Disease"},{"id":"1362","span":{"begin":1473,"end":1490},"obj":"Disease"},{"id":"1363","span":{"begin":1505,"end":1522},"obj":"Disease"},{"id":"1364","span":{"begin":1537,"end":1543},"obj":"Disease"},{"id":"1365","span":{"begin":1629,"end":1646},"obj":"Disease"},{"id":"1366","span":{"begin":1816,"end":1833},"obj":"Disease"},{"id":"1367","span":{"begin":1930,"end":1938},"obj":"Disease"},{"id":"1368","span":{"begin":2020,"end":2027},"obj":"Disease"},{"id":"1369","span":{"begin":2102,"end":2119},"obj":"Disease"},{"id":"1370","span":{"begin":2260,"end":2277},"obj":"Disease"},{"id":"1371","span":{"begin":2411,"end":2439},"obj":"Disease"},{"id":"1372","span":{"begin":2546,"end":2553},"obj":"Disease"},{"id":"1373","span":{"begin":2624,"end":2641},"obj":"Disease"},{"id":"1374","span":{"begin":2697,"end":2704},"obj":"Disease"},{"id":"1375","span":{"begin":2783,"end":2800},"obj":"Disease"},{"id":"1376","span":{"begin":2935,"end":2952},"obj":"Disease"},{"id":"1377","span":{"begin":3047,"end":3064},"obj":"Disease"},{"id":"1378","span":{"begin":3102,"end":3114},"obj":"Disease"},{"id":"1379","span":{"begin":3118,"end":3122},"obj":"Disease"},{"id":"1380","span":{"begin":3250,"end":3258},"obj":"Disease"},{"id":"1381","span":{"begin":3375,"end":3392},"obj":"Disease"},{"id":"1382","span":{"begin":3494,"end":3511},"obj":"Disease"},{"id":"1383","span":{"begin":3602,"end":3609},"obj":"Disease"},{"id":"1384","span":{"begin":3738,"end":3745},"obj":"Disease"},{"id":"1385","span":{"begin":3812,"end":3816},"obj":"Disease"},{"id":"1386","span":{"begin":3876,"end":3893},"obj":"Disease"},{"id":"1387","span":{"begin":4024,"end":4046},"obj":"Disease"},{"id":"1388","span":{"begin":4147,"end":4164},"obj":"Disease"},{"id":"1389","span":{"begin":4227,"end":4244},"obj":"Disease"},{"id":"1391","span":{"begin":17,"end":25},"obj":"Disease"}],"attributes":[{"id":"A1326","pred":"tao:has_database_id","subj":"1326","obj":"Gene:3569"},{"id":"A1327","pred":"tao:has_database_id","subj":"1327","obj":"Gene:3570"},{"id":"A1328","pred":"tao:has_database_id","subj":"1328","obj":"Gene:3554"},{"id":"A1329","pred":"tao:has_database_id","subj":"1329","obj":"Gene:3554"},{"id":"A1330","pred":"tao:has_database_id","subj":"1330","obj":"Gene:3570"},{"id":"A1331","pred":"tao:has_database_id","subj":"1331","obj":"Gene:3576"},{"id":"A1332","pred":"tao:has_database_id","subj":"1332","obj":"Gene:3576"},{"id":"A1333","pred":"tao:has_database_id","subj":"1333","obj":"Gene:3554"},{"id":"A1334","pred":"tao:has_database_id","subj":"1334","obj":"Gene:3458"},{"id":"A1335","pred":"tao:has_database_id","subj":"1335","obj":"Gene:3554"},{"id":"A1336","pred":"tao:has_database_id","subj":"1336","obj":"Gene:3458"},{"id":"A1337","pred":"tao:has_database_id","subj":"1337","obj":"Gene:1437"},{"id":"A1338","pred":"tao:has_database_id","subj":"1338","obj":"Gene:3716"},{"id":"A1339","pred":"tao:has_database_id","subj":"1339","obj":"Gene:3717"},{"id":"A1340","pred":"tao:has_database_id","subj":"1340","obj":"Gene:7124"},{"id":"A1341","pred":"tao:has_database_id","subj":"1341","obj":"Gene:3569"},{"id":"A1342","pred":"tao:has_database_id","subj":"1342","obj":"Gene:4513"},{"id":"A1343","pred":"tao:has_database_id","subj":"1343","obj":"Gene:1437"},{"id":"A1344","pred":"tao:has_database_id","subj":"1344","obj":"Tax:9606"},{"id":"A1345","pred":"tao:has_database_id","subj":"1345","obj":"Tax:9606"},{"id":"A1346","pred":"tao:has_database_id","subj":"1346","obj":"Tax:9606"},{"id":"A1347","pred":"tao:has_database_id","subj":"1347","obj":"Tax:9606"},{"id":"A1348","pred":"tao:has_database_id","subj":"1348","obj":"Tax:9606"},{"id":"A1349","pred":"tao:has_database_id","subj":"1349","obj":"Tax:9606"},{"id":"A1350","pred":"tao:has_database_id","subj":"1350","obj":"MESH:C000657245"},{"id":"A1351","pred":"tao:has_database_id","subj":"1351","obj":"MESH:C000657245"},{"id":"A1352","pred":"tao:has_database_id","subj":"1352","obj":"MESH:C000657245"},{"id":"A1353","pred":"tao:has_database_id","subj":"1353","obj":"MESH:C000657245"},{"id":"A1354","pred":"tao:has_database_id","subj":"1354","obj":"MESH:C000657245"},{"id":"A1355","pred":"tao:has_database_id","subj":"1355","obj":"MESH:C000657245"},{"id":"A1356","pred":"tao:has_database_id","subj":"1356","obj":"MESH:C000657245"},{"id":"A1357","pred":"tao:has_database_id","subj":"1357","obj":"MESH:C000657245"},{"id":"A1358","pred":"tao:has_database_id","subj":"1358","obj":"MESH:D016638"},{"id":"A1359","pred":"tao:has_database_id","subj":"1359","obj":"MESH:C000657245"},{"id":"A1360","pred":"tao:has_database_id","subj":"1360","obj":"MESH:C000657245"},{"id":"A1361","pred":"tao:has_database_id","subj":"1361","obj":"MESH:C000657245"},{"id":"A1362","pred":"tao:has_database_id","subj":"1362","obj":"MESH:C000657245"},{"id":"A1363","pred":"tao:has_database_id","subj":"1363","obj":"MESH:C000657245"},{"id":"A1364","pred":"tao:has_database_id","subj":"1364","obj":"MESH:D009369"},{"id":"A1365","pred":"tao:has_database_id","subj":"1365","obj":"MESH:C000657245"},{"id":"A1366","pred":"tao:has_database_id","subj":"1366","obj":"MESH:C000657245"},{"id":"A1367","pred":"tao:has_database_id","subj":"1367","obj":"MESH:C000657245"},{"id":"A1368","pred":"tao:has_database_id","subj":"1368","obj":"MESH:C000657245"},{"id":"A1369","pred":"tao:has_database_id","subj":"1369","obj":"MESH:C000657245"},{"id":"A1370","pred":"tao:has_database_id","subj":"1370","obj":"MESH:C000657245"},{"id":"A1371","pred":"tao:has_database_id","subj":"1371","obj":"MESH:C000657245"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"MESH:C000657245"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"MESH:C000657245"},{"id":"A1374","pred":"tao:has_database_id","subj":"1374","obj":"MESH:C000657245"},{"id":"A1375","pred":"tao:has_database_id","subj":"1375","obj":"MESH:C000657245"},{"id":"A1376","pred":"tao:has_database_id","subj":"1376","obj":"MESH:C000657245"},{"id":"A1377","pred":"tao:has_database_id","subj":"1377","obj":"MESH:C000657245"},{"id":"A1378","pred":"tao:has_database_id","subj":"1378","obj":"MESH:D007249"},{"id":"A1379","pred":"tao:has_database_id","subj":"1379","obj":"MESH:D012128"},{"id":"A1380","pred":"tao:has_database_id","subj":"1380","obj":"MESH:C000657245"},{"id":"A1381","pred":"tao:has_database_id","subj":"1381","obj":"MESH:C000657245"},{"id":"A1382","pred":"tao:has_database_id","subj":"1382","obj":"MESH:C000657245"},{"id":"A1383","pred":"tao:has_database_id","subj":"1383","obj":"MESH:C000657245"},{"id":"A1384","pred":"tao:has_database_id","subj":"1384","obj":"MESH:C000657245"},{"id":"A1385","pred":"tao:has_database_id","subj":"1385","obj":"MESH:D012128"},{"id":"A1386","pred":"tao:has_database_id","subj":"1386","obj":"MESH:C000657245"},{"id":"A1387","pred":"tao:has_database_id","subj":"1387","obj":"MESH:C000657245"},{"id":"A1388","pred":"tao:has_database_id","subj":"1388","obj":"MESH:C000657245"},{"id":"A1389","pred":"tao:has_database_id","subj":"1389","obj":"MESH:C000657245"},{"id":"A1391","pred":"tao:has_database_id","subj":"1391","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T69","span":{"begin":377,"end":391},"obj":"Phenotype"},{"id":"T70","span":{"begin":1537,"end":1543},"obj":"Phenotype"},{"id":"T71","span":{"begin":2935,"end":2944},"obj":"Phenotype"}],"attributes":[{"id":"A69","pred":"hp_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A70","pred":"hp_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A71","pred":"hp_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T136","span":{"begin":343,"end":347},"obj":"http://purl.obolibrary.org/obo/GO_0004915"},{"id":"T137","span":{"begin":2333,"end":2338},"obj":"http://purl.obolibrary.org/obo/GO_0004908"},{"id":"T138","span":{"begin":3102,"end":3114},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}

{"project":"LitCovid-sentences","denotations":[{"id":"T261","span":{"begin":0,"end":103},"obj":"Sentence"},{"id":"T262","span":{"begin":104,"end":237},"obj":"Sentence"},{"id":"T263","span":{"begin":238,"end":259},"obj":"Sentence"},{"id":"T264","span":{"begin":260,"end":430},"obj":"Sentence"},{"id":"T265","span":{"begin":431,"end":496},"obj":"Sentence"},{"id":"T266","span":{"begin":497,"end":563},"obj":"Sentence"},{"id":"T267","span":{"begin":564,"end":624},"obj":"Sentence"},{"id":"T268","span":{"begin":625,"end":695},"obj":"Sentence"},{"id":"T269","span":{"begin":696,"end":802},"obj":"Sentence"},{"id":"T270","span":{"begin":803,"end":948},"obj":"Sentence"},{"id":"T271","span":{"begin":949,"end":1088},"obj":"Sentence"},{"id":"T272","span":{"begin":1089,"end":1169},"obj":"Sentence"},{"id":"T273","span":{"begin":1170,"end":1294},"obj":"Sentence"},{"id":"T274","span":{"begin":1295,"end":1412},"obj":"Sentence"},{"id":"T275","span":{"begin":1413,"end":1581},"obj":"Sentence"},{"id":"T276","span":{"begin":1582,"end":1679},"obj":"Sentence"},{"id":"T277","span":{"begin":1680,"end":1759},"obj":"Sentence"},{"id":"T278","span":{"begin":1760,"end":1834},"obj":"Sentence"},{"id":"T279","span":{"begin":1835,"end":1957},"obj":"Sentence"},{"id":"T280","span":{"begin":1958,"end":2028},"obj":"Sentence"},{"id":"T281","span":{"begin":2029,"end":2181},"obj":"Sentence"},{"id":"T282","span":{"begin":2182,"end":2321},"obj":"Sentence"},{"id":"T283","span":{"begin":2322,"end":2481},"obj":"Sentence"},{"id":"T284","span":{"begin":2482,"end":2554},"obj":"Sentence"},{"id":"T285","span":{"begin":2555,"end":2713},"obj":"Sentence"},{"id":"T286","span":{"begin":2714,"end":2862},"obj":"Sentence"},{"id":"T287","span":{"begin":2863,"end":2953},"obj":"Sentence"},{"id":"T288","span":{"begin":2954,"end":3131},"obj":"Sentence"},{"id":"T289","span":{"begin":3132,"end":3151},"obj":"Sentence"},{"id":"T290","span":{"begin":3152,"end":3326},"obj":"Sentence"},{"id":"T291","span":{"begin":3327,"end":3444},"obj":"Sentence"},{"id":"T292","span":{"begin":3445,"end":3548},"obj":"Sentence"},{"id":"T293","span":{"begin":3549,"end":3681},"obj":"Sentence"},{"id":"T294","span":{"begin":3682,"end":3760},"obj":"Sentence"},{"id":"T295","span":{"begin":3761,"end":3825},"obj":"Sentence"},{"id":"T296","span":{"begin":3826,"end":3953},"obj":"Sentence"},{"id":"T297","span":{"begin":3954,"end":4069},"obj":"Sentence"},{"id":"T298","span":{"begin":4070,"end":4165},"obj":"Sentence"},{"id":"T299","span":{"begin":4166,"end":4262},"obj":"Sentence"},{"id":"T300","span":{"begin":4263,"end":4336},"obj":"Sentence"},{"id":"T301","span":{"begin":4337,"end":4417},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 2 List of COVID-19 clinical trials investigating immunotherapies for mitigating immunopathology.\nCategory Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)\nAnti-cytokine therapy\n      Anti IL-6 Tocilizumab NCT04315480 II Italy 38 Pneumatic COVID19+ Anti-IL6R mAB to prevent virus-related cytokine storm and reduce symptoms of severe COVID-19\nTocilizumab NCT04317092 II Italy (27) 400 Pneumatic COVID19+\nTocilizumab NCT04320615 III Not listed 330 Pneumatic COVID19+\nTocilizumab NCT04332913 N/A Italy 30 Pneumatic COVID19+\nTocilizumab NCT04335071 II Switzerland (3) 100 Pneumatic COVID19+\nTocilizumab NCT04322773 II Denmark (2) 200 Pneumatic COVID19+ I.V. vs. S.C. routes of administration\nTocilizumab NCT04331795 II Illinois, USA 50 COVID19+, not on ventilator Low (80mg) vs. standard dose (200mg) in non-critically ill patients\nTocilizumab NCT04346355 II Italy (24) 398 Pneumatic COVID19+, non-ICU Early administration of tocilizumab on reduced ventilation time\nTocilizumab NCT04331808 II Paris, France 240 Group 1: non-ICU; Group 2: ICU\nTocilizumab (vs. CRRT) NCT04306705 N/A Hubei, China 120 Pneumatic COVID19+ CRRT = continuous renal replacement therapy\nTocilizumab (vs. Anakinra) NCT04339712 II Greece (17) 20 Pneumatic COVID19+, non-ICU Anakinra - IL1r antagonist\nTocilizumab (vs. GNS651) NCT04333914 II France (4) 273 Pneumatic COVID19+ Efficacy in COVID19+ advanced or metastatic cancer patients; GNS651 = chloroquine analog\nSarilumab NCT04315298 II/III USA (57) 400 Pneumatic COVID19+ Low vs. high dose of sarilumab\nSarilumab NCT04324073 II/III France (4) 239 Group 1: non-ICU; Group 2: ICU\nSarilumab NCT04327388 II/III Canada+France (8) 300 Pneumatic COVID19+\nHydroxychloroquine + Axithromycin ± Tocilizumab NCT04332094 II Barcelona, Spain 276 Early COVID19+, not on ventilator\nTocilizumab + Favipiravir NCT04310228 N/A China (11) 150 COVID19+\nTocilizumab + Anakinra + Siltuximab NCT04330638 III Belgium (9) 342 Pneumatic COVID19+ Anakinra - IL1r antagonist and Siltuximab - IL6r antagonist\n      Anti-IL-8 Anti-IL-8 (BMS-986253) NCT04347226 II New York, USA 138 Pneumatic COVID19+ Prevent recruitment of inflammatory cells\n      Anti IL-1R/Anti IFNγ Anakinra vs. Emapalumab NCT04324021 II/III Italy (4) 54 Pneumatic COVID19+ Anakinra (IL1r antagonist); Emapalumab (anti-IFNγ)\nAnakinra ± Ruxolitinib NCT04366232 II France (3) 54 Severe COVID19+\n      Anti-GM-CSF Mavrilimumab NCT04337216 II Virginia, USA 10 Pneumatic COVID19+ GM-CSF is one of the main mediators of CRS in severe COVID19 patients\n      Jak Inhibitor Baricitinib NCT04399798 II Pavia, Italy 13 Pneumatic COVID19+ Inhibits JAK1-/JAK2-mediated cytokine release and TNF-alpha\nRitonavir ± Baricitinib NCT04320277 III Tuscany, Italy 60 Moderate/pneumonia COVID19+\n      Extracorporeal adsorption CytoSorb absorber NCT04324528 N/A Freiburg, Germany 30 Pneumatic COVID19+ “Absorbs” IL-6 in effort to reduce inflammation in ARDS patients\nAnti-inflammatories\n      Corticosteroid Ciclesonide ± Hydroxychloroquine NCT04330586 II Seoul, Korea 141 Early COVID19+ (within 7 days) Ciclesonide is an anti-inflammatory corticosteroid\nPrednisone NCT04344288 II Bron, France 304 Pneumatic COVID19+ Prednisone is an anti-inflammatory corticosteroid\nHydrocortisone NCT04348305 III Denmark 1000 Pneumatic COVID19+ Low-dose hydrocortisone for 7 days\nDexamethasone NCT04344730 N/A Paris, France 550 COVID19+ ICU within 48hrs Dexamethasone is an anti-inflammatory corticosteroid\nDexamethasone NCT04325061 IV Spain (24) 200 Severe COVID19+ on ventilator\nDexamethasone NCT04327401 III Brazil (21) 290 ARDS patients\nMethylprednisolone NCT04343729 II Brazil 420 Pneumatic COVID19+ Methylprednisolone is an anti-inflammatory corticosteroid\nMethylprednisolone (vs. Tocilizumab) NCT04345445 III Kuala Lumpur, Malaysia 310 COVID19+ with high risk of CRS\nMethylprednisolone (vs. Siltuximab) NCT04329650 II Barcelona, Spain 200 Pneumatic COVID19+\n      NSAID Naproxen NCT04325633 III Paris, France 584 Pneumatic COVID19+ COX-2 inhibitor\nIbuprofen NCT04334629 IV Not listed 230 NEWS2 \u003e 5 overall, Pneumatic\nNEWS, National Early Warning Score; HCW, Healthcare Workers; As of June 1, 2020."}